ABSTRACT: Parasitic nematodes pose a serious threat to agriculture, livestock, and human health. Increasing resistance to antiparasitic agents underscores the need to replenish our anthelmintic arsenal. The nonpathogenic Caenorhabditis elegans, which serves as an effective model of parasitic helminths, has been used to search for new anthelmintic leads. We previously reported small-molecule inhibitors of the essential C. elegans protein UDP-galactopyranose mutase (UGM or Glf). This enzyme is required for the generation of galactofuranose (Galf)-containing glycans and is needed in nematodes for proper cuticle formation. Though our firstgeneration inhibitors were effective in vitro, they elicited no phenotypic effects. These findings are consistent with the known difficulty of targeting nematodes. C. elegans is recalcitrant to pharmacological modulation; typically, less than 0.02% of small molecules elicit a phenotypic effect, even at 40 μM. We postulated that the lack of activity of the UGM inhibitors was due to their carboxylic acid group, which can be exploited by nematodes for detoxification. We therefore tested whether replacement of the carboxylate with an N-acylsulfonamide surrogate would result in active compounds. UGM inhibitors with the carboxylate mimetic can phenocopy the deleterious consequences of UGM depletion in C. elegans. These findings support the use of UGM inhibitors as anthelmintic agents. They also outline a strategy to render small-molecule carboxylates more effective against nematodes. N ematodes include both parasitic organisms (helminths) and free-living species such as the model organism Caenorhabditis elegans.
N ematodes include both parasitic organisms (helminths) and free-living species such as the model organism Caenorhabditis elegans. 1−6 Human infections by parasitic nematodes cause worldwide suffering, especially within the developing world. Over 1.5 billion people are infected with helminths, corresponding to 24% of the world's population. 7−9 Helminth damage extends beyond direct human infection. In the United States alone, helminths cause annual losses estimated at $2 billion in the cattle industry and $80 billion in crop damage.
10, 11 The emergence of anthelmintic resistance has spurred the search for new strategies with which to combat the parasites. 12 The helminth glycocalyx can modulate host immune responses, 13−18 while serving as a critical protective barrier. 19 Thus, understanding the roles of glycans in parasitic nematodes could uncover new strategies to combat these pathogens.
Extracellular glycoconjugates are critical components of the protective nematode exoskeleton termed the cuticle. Cuticle glycoconjugates and the collective outer glycocalyx are needed for nematode motility and structural integrity. One proposed component of this glycocalyx is the thermodynamically disfavored isomer of galactose: galactofuranose (Galf). The production of Galf-containing glycoconjugates requires the enzyme uridine 5′-diphosphate (UDP) galactopyranose mutase (UGM or Glf). UGM, which is encoded by the glf-1 ortholog present in the free-living nematode C. elegans, 20 catalyzes the interconversion of UDP-galactopyranose (UDP-Galp) and UDP-galactofuranose (UDP-Galf) 20, 21 ( Figure 1 ). Biochemical characterization of C. elegans UGM (CeUGM) authenticated its ability to interconvert UDP-Galp and UDP-Galf, 22 and deletion of this gene revealed a crucial role for UGM in nematode development. 23, 24 Although Galf residues have yet to be identified within any specific nematode glycoconjugate, the deleterious effects of UGM deletion suggest that Galfcontaining glycans have essential roles.
25−27 UGM orthologs are encoded by parasitic helminths including Brugia malayi, Ascaris, Brugia, and Dirof ilaria spp. 22, 28, 29 In contrast, humans lack Galf residues and therefore UGM. Together, these analyses provide impetus to elucidate UGM and Galf function in nematodes.
Small molecule probes of UGM would be valuable tools to examine the importance of the enzyme in nematodes. Indeed, compounds that have been reported to block UGM activity also act against Brugia malayi.
30 There are two concerns with these observations, however. First, UGM produced from all other organisms is dimeric, while the B. malayi ortholog was reported to be decameric. The unexpected oligomerization state raises questions about whether the active form of the enzyme was isolated, and the experiments purported to quantify enzyme activity did not directly monitor UDP-Galf formation. Second, the putative inhibitors are members of the PAINS (pan assay interference compounds) family. Conclusions about their activity and mechanism of action cannot be drawn without additional experiments. 31 As a result, evidence was lacking that UGM inhibitors are deleterious to nematodes.
We sought inhibitors of UGM that could assess its suitability as a target for anthelmintics. Our plan was to adapt the prokaryotic UGM inhibitors previously described by our group 32−34 for use in nematodes. We had identified two distinct classes of competitively binding small-molecule UGM inhibitors with antimycobacterial potency (Figure 1 ). The first class includes compounds containing a 2-aminothiazole core 35, 36 that can impede both mycobacterium tuberculosis UGM activity and mycobacterial growth. 37 Virtual screening afforded a second class of inhibitors, triazolothiadiazines, which also were effective against mycobacteria. 38 Despite little sequence homology between CeUGM and prokaryotic UGM enzymes, 20 mechanistic and active site similarities between UGM orthologs allow compounds from each inhibitor class to function as potent inhibitors of CeUGM. 22, 38 Parasitic nematodes have complex life-cycles that complicate anthelmintic screening. As a nonpathogenic organism C. elegans is a free-living nematode that effectively models helminth biology and therefore serves as a simple model organism. [1] [2] [3] 6 These properties, combined with our previous experience characterizing CeUGM, led us to focus on testing inhibitors against C. elegans. Still, like other nematodes, C. elegans is challenging to target with small molecules. 39 Pharmacological probes are typically used in worms at concentrations that are orders of magnitude higher than those employed in tissue culture. 40, 41 The need for high probe concentrations to elicit phenotypic effects on nematodes has been attributed to two factors. First, the C. elegans genome encodes an array of enzymes to disarm xenobiotics; these include 86 cytochrome P450 enzymes, 72 glutathione S-transferases (GSTs), and 48 glucuronosyltransferases (UGTs). 42 Second, the nematode cuticle, composed of a network of collagen and glycoconjugates, creates a formidable and highly impermeable barrier to small molecules. 43 Herein, we describe inhibitors of CeUGM that can circumvent these barriers and thereby disrupt the nematode life cycle.
■ RESULTS AND DISCUSSION
Targeting UGM within C. elegans. Deletion of the gene encoding CeUGM (glf-1) significantly impairs C. elegans development. 23 The most notable phenotype is 95% lethality, which occurs in the late stages of embryogenesis and early stages of larval development. Similarly, RNA interference of glf-1 in the parasitic species Brugia malayi results in larval lethality. 24 Experiments by Novelli et al. indicate that CeUGM production can first be detected after completion of cuticle synthesis, 1 h prior to hatching. In L4 larvae and adults, the enzyme is found predominantly in the seam cells, which are responsible for producing the carbohydrate-rich surface coat. 44 Nematodes deficient in glf-1 exhibit distinctive phenotypes that are indicative of a defective surface coat, including impaired motility and compromised cuticle integrity. 45−47 These data suggest Galf glycoconjugates are important constituents of the cuticle.
The consequences of glf-1 deletion suggest that UGM could serve as an anthelmintic target. When known UGM inhibitors were assessed with wild-type C. elegans (N2), however, no effect on proliferation, development, or morphology was detected. The disparity between in vitro and in vivo efficacy of CeUGM inhibitors was disappointing, yet consistent with the difficulties of targeting C. elegans using small molecules. Nematodes employ the previously mentioned defensive features, their cuticle and detoxification mechanisms, to shield themselves from small molecule probes. 42,48−50 We hypothesized that at least one of these protective features mitigated the effects of the UGM inhibitors.
To circumvent nematode defense, we modified the inhibitor structure. A shared feature of the inhibitors tested is a carboxylate group, which we identified as a potential liability. Though the negatively charged carboxylate is not conducive to membrane permeability, our major concern was that carboxylate groups act as reactive sites for detoxification enzymes. Enzymes such as UDP-glucuronosyltransferase can convert a small-molecule carboxylate into an acylglucuronide, thereby rendering it inactive ( Figure 2) . 51 SAR studies of UGM inhibitors, however, indicate the carboxylate negative charge is critical for potency. 52 We therefore sought a carboxylate mimetic likely to evade detoxification enzymes. We previously 
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Articles found N-acylsulfonamide groups were effective carboxylate surrogates, as they are anionic at physiological pH values. 52 Inhibitors with an N-acylsulfonamide group not only blocked MtbUGM enzymatic activity but were superior to their carboxylate counterparts at permeating the mycobacterial cell wall and therefore were more potent antimycobacterial agents. Accordingly, we evaluated their activity against nematodes.
N-Acylsulfonamide Analogs Inhibit CeUGM Catalysis. To compare inhibitor potency, we synthesized compounds 1− 14.
52 These analogs were tested for their ability to impede the catalytic activity of CeUGM. 22 Carboxylate-containing compounds 1 and 11 were active, but the corresponding methyl esters (compounds 10 and 14) were significantly less potent. In contrast, each derivative bearing an anionic N-acylsulfonamide group was at least equivalent, if not superior, at inhibiting CeUGM compared to the corresponding carboxylate ( Table 1,   Table 2 ). These results support our previous findings that the N-acylsulfonamide group functions as an effective carboxylate surrogate 52 ( Table 1 ). The most potent inhibitor identified was the chlorophenylsulfonamide 8 (IC 50 = 0.7 ± 0.3 μM).
Activity of UGM Inhibitors in Nematodes. We assessed the effects of the N-acylsulfonamide CeUGM inhibitors on C. elegans. Initial testing was performed by synchronizing C. elegans as embryos and exposing them to compounds 1−14 (250 μM) dissolved in agar. As anticipated from our previous findings, neither carboxylate 1 nor 11 affected growth, and animals treated with either carboxylate appeared phenotypically normal and healthy. We also tested the corresponding methyl esters 10 and 14. Though ineffective as CeUGM inhibitors as esters, they could serve as pro-inhibitors if unmasked by cellular esterases. However, neither methyl ester variant restricted reproduction or development. In contrast, several N-acylsulfonamide derivatives impeded nematode development and proliferation (Tables 1 and 2 ). When nematodes were maintained on nematode growth medium (NGM) supplemented with compound 4 or 8, their development was severely restricted. Four days following synchronization, only larva were present. These larva either failed to produce progeny upon reaching adulthood or failed to reach adulthood altogether. More effective inhibitors, such as 2, 3, 5, and 9, resulted in near complete embryonic lethality; no viable animals were present 4 days following synchronization. Thus, strategic substitution of the carboxylic acid moiety affords inhibitors that act on nematodes.
To compare inhibitor potency quantitatively, we evaluated the concentration dependence of C. elegans inhibition (Tables 1  and 2 ). We assessed the effective concentration at which growth and proliferation is eliminated (EC 100 value). Compounds 4 and 8 had little effect on nematode proliferation at concentrations lower than 250 μM. In contrast, compounds 5 and 9 had EC 100 values of 150 μM. Compounds 2 and 3, which blocked nematode proliferation at 100 μM, were the most efficacious.
We further evaluated the impact of UGM inhibitors on C. elegans. We synchronized nematodes and assessed the results of UGM inhibitor exposure after 48 h ( Figure 3A ). As expected, compounds 2 and 4, which both have measurable EC 100 values, afforded substantial lethality. Compared to untreated controls, many dead embryos were visible, and the number of animals decreased. Additionally, animals treated with 2 or 4 exhibited developmental delays. At 48 h following synchronization, the surviving animals were at the L2 or L3 stages, and very few animals treated with 4 had reached adulthood. Consistent with our EC 100 determinations, proliferation of animals treated with 2 was completely blocked, and no animals that hatched reached adulthood, even 12 days following synchronization. At 48 h after treatment, animals treated with 1 were healthy and progressed through development at the same rate as untreated controls ( Figure 3B ). However, as observed with exposure to compounds 2 and 4, carboxylate 1 led to many dead embryos. Indeed, this inhibitor caused a statistically significant reduction in viable animals. The activity of 1 came as a surprise, because a The relative activity of recombinant CeUGM was evaluated in the presence of inhibitor. Error values represent the standard deviation from the mean (n ≥ 2). b The relative activity of recombinant CeUGM was evaluated for a range of inhibitor concentrations. Data were analyzed using nonlinear regression analysis with a one-site binding model. The calculated half-maximal inhibition concentration (IC 50 ) is provided with the standard deviation (n ≥ 2).
c All EC 100 values ≤250 μM represent data from synchronized embryos cultured on compound-embedded agar (see methods). a The relative activity of recombinant CeUGM was evaluated in the presence of inhibitor. Error values represent the standard deviation from the mean (n ≥ 2). b The relative activity of recombinant CeUGM was evaluated for a range of inhibitor concentrations. Data were analyzed using nonlinear regression analysis with a one-site binding model. The calculated half-maximal inhibition concentration (IC 50 ) is provided with the standard deviation (n ≥ 2).
c All EC 100 values ≤250 μM represent data from synchronized embryos cultured on compound-embedded agar (see methods).
Articles our previous experiments indicated compound 1 had no detectable EC 100 concentration. These data indicate that the impact of carboxylate-containing compound 1 is short-lived relative to that of N-acylsulfonamide-containing compounds 2 and 4.
The basis for the enhanced biological potency of acylsulfonamides relative to their carboxylate counterparts was assessed. Installing a carboxylate mimetic could either improve inhibitor permeability or circumvent detoxication enzymes such as glucuronosyltransferases. To assess permeability, we exposed C. elegans to compound 1 or 2 and quantified inhibitor levels (see Supporting Information). The concentration of each compound accumulated within C. elegans was similar, suggesting the enhanced potency of carboxylate surrogates is not due to differences in permeability. The comparable accumulation levels of 1 and 2 and the transient action of 1 relative to 2 suggest that the N-acylsulfonamide derivatives resist detoxification and therefore persist as UGM inhibitors.
Phenotype Induced by UGM Inhibitors. We examined the phenotypic effects elicited by the N-acylsulfonamide UGM inhibitors. Sublethal concentrations (50 μM and 25 μM) of compounds 2 or 3 elicited phenotypic responses. Specifically, inhibitor-treated animals displayed lengthy development delays. Typically, untreated animals took approximately 48 h to reach adulthood, while animals exposed to 3 (25 μM) took 4−6 days ( Figure 4A ). Additionally, UGM inhibitor exposure led to a wide range of developmental delays, and some animals failed to progress to adulthood altogether. For example, some animals cultivated with 50 μM 3 persisted as larvae for up to 19 days. The ability of UGM inhibitors to induce these deleterious effects is notable; fewer than 0.02% of compounds tested (40 μM) in a high throughput nematode screen exhibited phenotypic effects. 40 Evidence indicates that the phenotypic effects result from UGM inhibition. Deletion of glf-1 in C. elegans results in lethality during embryonic and larval stages, which is consistent with observations that glf-1 is most highly expressed in late embryonic development. 53, 23 Similarly, worms exposed to UGM inhibitors afforded extensive lethality during late embryonic development. Moreover, UGM inhibitor-treatment in nematodes resulted in motion defects reminiscent of the Skd phenotype. This phenotype, also displayed by glf-1 null animals, is characterized by poor traction on agar surfaces. 23 Animals treated with 25 μM compound 3 move normally within the bacterial lawns but display a traction defect on agar ( Figure 4B , videos in Supporting Information). This rare phenotype has been predominantly observed in C. elegans mutants of cuticle glycosylation. 3 Another characteristic of impaired cuticle formation displayed by both glf-1 null mutants and glf-1 knock-down worms is hypersensitivity to hypochlorite-induced rupturing. We therefore subjected UGM inhibitor-treated worms to the hypochlorite-induced rupture assay ( Figure  4C ). Nematodes exposed to 2 or 4 (50 μM) ruptured more rapidly (in about half the time) than untreated nematodes. Notably, the rapid-rupture phenotype was not elicited by carboxylate 1. Thus, the N-acylsulfonamide but not carboxylate UGM inhibitors were effective against adult nematodes. Together, the data reveal that UGM inhibitors phenocopy unique aspects of glf-1 deletion, indicating that the characteristic phenotypic defects result from CeUGM inhibition.
A more stringent test of the target is to ascertain whether glf-1 depletion sensitizes C. elegans to UGM inhibitors. Reduction of UGM levels should augment the effects of UGM inhibitor treatment. In accord with this prediction, the EC 100 of 3 decreased to 50 μM in glf-1 knock-down worms, and the developmental delays observed in glf-1 knock-down worms were longer than those undisturbed by genetic interference (see Supporting Information). These results, in conjunction with our other data, are consistent with a model in which the acylsulfonamide UGM inhibitors act on target.
Conclusions. Nematodes possess powerful defense mechanisms. Their cuticle and rapid metabolism of xenobiotic compounds are attributes that function as a formidable barrier to small-molecule probes and drugs. Our observation that previous generations of UGM inhibitors lacked antinematode activity, despite efficacy against purified enzymes, was consistent with these challenges. We postulated that the Achilles heel of these inhibitors was their carboxylate group and therefore generated inhibitors that could circumvent nematode defense mechanisms. In replacing the carboxylic acid with an N-acylsulfonamide, we produced inhibitors that phenocopy many aspects of the glf-1 deletion mutants. Our findings indicate that carboxylate group replacement improved the metabolic stability of the UGM inhibitors. We anticipate that the use of carboxylate surrogates will be a general strategy Figure 3 . (A) Live C. elegans animals were counted after synchronization. All UGM inhibitors (100 μM) induced a statistically significant decrease in survival 48 h following synchronization (*p value < 0.05, **p value < 0.01, ***p value < 0.005). (B) Number of adults at 48 h. Animals that survived late embryogenesis in the presence of compound 1 were healthy and developed normally. In contrast, animals treated with 2 or 4 were developmentally delayed. NGM: nematode growth medium.
Articles to boost the efficacy of carboxylic acid-bearing small molecules against nematodes.
We anticipate that the UGM inhibitors described herein can be used to probe the role of Galf in nematode glycoconjugates. The available data suggest that nematodes generate galactofuranose-containing cell-surface glycans that function as vital constituents of the cuticle, but as yet are unidentified. Because surface glycoconjugates of C. elegans are similar to those of parasitic nematodes, we anticipate our UGM inhibitors can be used to probe helminth biology and further evaluate the utility of UGM as an anthelmintic target. An additional impetus to pursue this direction is found in the results of disruption of glf-1 in the parasite Brugia malayi, which afforded impaired motility and embryogenesis and reduced microfilarial release. 24 As helminth glycoconjugates likely facilitate evasion of host immune defenses, a deeper understanding of the composition and roles of nematode glycoconjugates could lead to new strategies with which to combat infection. To this end, we note that glf-1 deficient C. elegans display hypersensitivity to ivermectin and other anthelmintics, 23 thereby raising the prospect that UGM inhibitors could be used to enhance drug sensitivity in anthelmintic-resistant nematodes.
■ METHODS
Compound Synthesis. The carboxylate 2-aminothiazole 1 was synthesized according to published protocols. 37 Synthetic procedures for carboxylate modification to N-acylsulfonamide or ester derivatives of either 1 or the commercially available 11 were performed as described. 52 Evaluation of CeUGM Activity. Recombinant CeUGM was produced according to published protocols, 22 and enzyme activity was evaluated using a previously described HPLC assay. 32 Briefly, CeUGM in sodium phosphate buffer (50 mM sodium phosphate, pH 7.0) was mixed with dithionite (10 mM) and the substrate UDP-Galf (12 μM) in either the absence or presence of an inhibitor (added as a DMSO stock for a final concentration of 1% DMSO). Inhibitor concentrations ranged from 50 nM to 25 μM. After 4 min, the enzymatic reaction was quenched by the addition of an equal volume of 1:1 methanol/ chloroform. The aqueous portion was separated by centrifugation and analyzed by HPLC using a Dionex Carbopac PA-100 column (200 mM ammonium acetate, pH 8.0, 0.6 mL/min) to quantify conversion of UDP-Galf to UDP-Galp. Relative enzyme activity was derived by normalizing activity in the presence of inhibitors against the activity of the enzyme alone. Inhibition curves were plotted using GraphPad Prism 6, and IC 50 values were derived using a one-site linear regression model.
Determination of EC 100 . Compounds were supplemented into NGM (nematode growth medium) at the indicated concentration from a DMSO stock solution. 54 C. elegans were then synchronized via treatment with alkaline hypochlorite solution. 54 Embryos were then transferred to plates supplemented with the compound and grown at 22°C using OP-50 as a food source. Preliminary screening for efficacy was performed in 24-well tissue culture plates; all compounds (250 μM) were tested in triplicate. Those compounds that showed activity in whole worms were evaluated at lower concentrations in triplicate (150 μM, 100 μM, 50 μM) by using compound-supplemented NGM in 10 mm plates. The EC 100 value, the concentration of compound that blocked all C. elegans proliferation, was determined in two stages. For EC 100 testing at 250 μM, growth was monitored 4 days following synchronization. Those compounds that appeared most active were examined further. For all subsequent testing at 150 μM, 100 μM, and 50 μM, growth was monitored for 12 days following synchronization.
Quantification of Embryonic Inhibitor Lethality and Assessment of Developmental Delays. Compounds were added to NGM (nematode growth medium) at the indicated concentration. 54 C. elegans were synchronized via treatment with alkaline hypochlorite solution, and an egg suspension (50−75 eggs/plate) was pipetted onto NGM plates. 54 Unless otherwise noted, the number of animals/total number of adult animals was tabulated 48 h after synchronization. Results are representative of independent biological replicates, each conducted in triplicate. Development was typically monitored for 10 days or until plates were depleted of nutrients.
RNAi Knock-Down of glf-1 and Treatment with UGM Inhibitors. RNAi knock-down of glf-1 (Gene H04M03.4) was performed by feeding as previously described using the relevant strain from the RNAi feeding library. 55 The compound was supplemented into NGM (Nematode Growth Media) from a DMSO stock solution at the indicated concentration, along with carbenicillan to 25 μg/mL and IPTG to 1 mM. 54 Assays were conducted in 24-well tissue culture plates.
Prior to determination of UGM inhibitor sensitivity, C. elegans were maintained on either H04M03.4 knockdown or L4440 empty vector control. Gravid hermaphrodites were then synchronized via treatment with alkaline hypochlorite solution. An egg suspension of either glf-1 knockdown or control C. elegans was then pipetted onto NGM plates supplemented with compound. The day prior to synchronization, 
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Articles either H04M03.4 knock-down E. coli or L4440 empty vector control E. coli were added to allow ample time for induction of knock-down RNAi. 54 Compounds 1, 3, and 8 were tested along with a DMSO control. Each compound was tested in triplicate at 25 μM, 50 μM, 100 μM, or 200 μM, with final DMSO concentrations of 0.05%, 0.1%, 0.2%, and 0.4%, respectively. Observations regarding development of C. elegans grown in the presence of 8 were made 72 h postsynchronization. Determinations of EC 100 were made 12 days following synchronization.
Hypochlorite Sensitivity. Sensitivity to alkaline hypochlorite was measured as a proxy for cuticle integrity. 3 Animals were grown on NGM supplemented with the compound of interest (50 μM). The compound was applied from an ethanol stock solution (50 mM). Adult worms were individually transferred to an NGM plate, and 20 μL of alkaline hypochlorite solution was dropped onto the worm. Reagent grade sodium hypochlorite solution (Sigma, available chlorine 10−15%) was used. Prior to use in the assay, sodium hypochlorite solution was diluted 4-fold, and sodium hydroxide was added to 0.25 M. The time until first rupture was measured. Statistical outliers were determined by the Thompson tau technique. 56 Each treatment group was composed of ≥20 nematodes. Data are representative of two separate experiments.
Evaluation of Skd Phenotype. C. elegans were synchronized by hypochlorite treatment. Embryos were transferred to a 24 well plate, with wells containing NGM supplemented with 25 μM 3. Upon reaching adulthood, animals were transferred to NGM agar plates and traction was observed. Representative videos of animals displaying a Skd phenotype were collected (Videos S1−S5).
Nematode Permeability of Small Molecules. The permeability assay was conducted by adapting a known protocol (see the Supporting Information).
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